

Product Data Sheet

Product Name: CNX-2006

Cat. No.: GC11264

Chemical Properties

Cas. No. 1375465-09-0

Chemical Name N-(3-((2-((4-((1-(2-fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-(trifluoroethyl)pyrimidin-4-yl)amino)phenyl)acrylamide

SMILES FC(F)(F)C1=CC(NC2=CC(NC(C=C)O)=CC=C2)N=C(NC3=CC=C(NC4CN(CCCF)C4)C=C3OC)N=C1

Formula $C_{26}H_{27}F_4N_7O_2$

M.Wt 545.53


Solubility $\geq 27.3\text{mg/mL}$ in DMSO

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

CNX-2006, a structural analog of CO-1686, is a selective and irreversible inhibitor of mutant-EGFR

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

with IC₅₀ value of < 20 nM.

The epidermal growth factor receptor (EGFR) is the cell-surface receptor for epidermal growth factor and plays an important role in tumor invasion and cancer cell proliferation.

CNX-2006 is a novel and irreversible mutant-selective EGFR inhibitor with very weak inhibition of wild-type EGFR. In non-small cell lung cancer (NSCLC) models expressing mutant EGFR-T790M, CNX-2006 inhibited EGFR signaling. CNX-2006 acquired resistance which was driven by NF-κB. So NF-κB activation might replace the EGFR signaling. These results suggested that inhibition of NF-κB pathway was a promising therapy method for patients who progressed after treatment with mutant-selective EGFR inhibitors [1].

Reference:

[1]. Galvani E, Sun J, Leon LG, et al. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. *Oncotarget*, 2015.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA